-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-The Financial Express A patent law that is transparent, based on principles of good science & encourages innovation is in India's interest In 500 BC, in the Greek city of Sybaris, it was proclaimed that "encouragement was held out to all who should discover any new refinement in luxury, the profits arising from which were secured to the inventor by patent for the space of a year." England followed with the Statute...

-The Hindu   Despite apparent similarities, the reports of two centrally appointed committees are split on the relationship between knowledge, skills and social needs Two major reports with overlapping concerns were submitted to the central government during the last decade. They were drafted by committees appointed by two different offices of the same government. One was chaired by Yash Pal, and the other by Sam Pitroda. The titles of the two committees indicated...

-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...

-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...